A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
Titel:
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
Auteur:
Kolinsky, M.P. Rescigno, P. Bianchini, D. Zafeiriou, Z. Mehra, N. Mateo, J. Michalarea, V. Riisnaes, R. Crespo, M. Figueiredo, I. Miranda, S. Nava Rodrigues, D. Flohr, P. Tunariu, N. Banerji, U. Ruddle, R. Sharp, A. Welti, J. Lambros, M. Carreira, S. Raynaud, F.I. Swales, K.E. Plymate, S. Luo, J. Tovey, H. Porta, N. Slade, R. Leonard, L. Hall, E. de Bono, J.S.